PB systems were successfully used to generate CD19 CARs for hematological malignancies [45] as well as CARs against selected solid tumor antigens, such as CD73 [46], MSLN [47], EGFRvIII [48], and PSMA [49]. This evidence concerns the gene CD19 and hematologic disorder.